DE69826124D1 - Verabreichung der nukleinsäure in den quergestreiften muskel - Google Patents

Verabreichung der nukleinsäure in den quergestreiften muskel

Info

Publication number
DE69826124D1
DE69826124D1 DE69826124T DE69826124T DE69826124D1 DE 69826124 D1 DE69826124 D1 DE 69826124D1 DE 69826124 T DE69826124 T DE 69826124T DE 69826124 T DE69826124 T DE 69826124T DE 69826124 D1 DE69826124 D1 DE 69826124D1
Authority
DE
Germany
Prior art keywords
nucleic acid
molecule
administration
muscle cell
sup
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69826124T
Other languages
English (en)
Other versions
DE69826124T3 (de
DE69826124T2 (de
Inventor
Michel Bureau
Lluis Mit
Daniel Scherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy (IGR)
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26233648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69826124(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9708233A external-priority patent/FR2765242B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Gustave Roussy (IGR), Aventis Pharma SA filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE69826124D1 publication Critical patent/DE69826124D1/de
Application granted granted Critical
Publication of DE69826124T2 publication Critical patent/DE69826124T2/de
Publication of DE69826124T3 publication Critical patent/DE69826124T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/0404Electrodes for external use
    • A61N1/0408Use-related aspects
    • A61N1/0412Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
    • A61N1/0416Anode and cathode
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69826124T 1997-06-30 1998-06-30 Verabreichung der nukleinsäure in den quergestreiften muskel Expired - Lifetime DE69826124T3 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9708233 1997-06-30
FR9708233A FR2765242B1 (fr) 1997-06-30 1997-06-30 Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
US6748897P 1997-12-01 1997-12-01
US67488P 1997-12-01
PCT/FR1998/001400 WO1999001158A1 (fr) 1997-06-30 1998-06-30 Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede

Publications (3)

Publication Number Publication Date
DE69826124D1 true DE69826124D1 (de) 2004-10-14
DE69826124T2 DE69826124T2 (de) 2005-09-15
DE69826124T3 DE69826124T3 (de) 2007-10-11

Family

ID=26233648

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69826124T Expired - Lifetime DE69826124T3 (de) 1997-06-30 1998-06-30 Verabreichung der nukleinsäure in den quergestreiften muskel

Country Status (16)

Country Link
US (1) US6939862B2 (de)
EP (1) EP0991426B2 (de)
JP (1) JP2002507985A (de)
KR (1) KR20010020571A (de)
CN (1) CN1261807A (de)
AT (1) ATE275423T1 (de)
AU (1) AU8444798A (de)
BR (1) BR9810369A (de)
CA (1) CA2294793A1 (de)
CZ (1) CZ299473B6 (de)
DE (1) DE69826124T3 (de)
HU (1) HUP0004589A3 (de)
IL (1) IL133710A0 (de)
NO (1) NO328102B1 (de)
PL (1) PL337583A1 (de)
WO (1) WO1999001158A1 (de)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1261808A (zh) * 1997-06-30 2000-08-02 罗纳-布朗克罗莱尔股份有限公司 向多细胞真核生物的细胞中转移核酸的改进方法和用于实施该方法的组合
US20090239940A1 (en) * 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
US6800484B2 (en) 1998-06-24 2004-10-05 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
US7922709B2 (en) 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US6678556B1 (en) * 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
CA2377565A1 (en) * 1999-06-25 2001-01-04 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
CA2402530C (en) 2000-03-13 2014-01-14 Cornell Research Foundation, Inc. Blocking leukocyte emigration and inflammation by interfering with cd99
WO2001079299A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
JP2004532654A (ja) 2000-05-22 2004-10-28 マーク・アンド・カンパニー・インコーポレイテッド 薬剤投与システム性能評価システム及び方法
GB2374018B (en) 2000-11-17 2003-11-19 Gendel Ltd Ultrasound therapy
US6821274B2 (en) 2001-03-07 2004-11-23 Gendel Ltd. Ultrasound therapy for selective cell ablation
IL155726A0 (en) 2000-12-28 2003-11-23 Wyeth Corp Recombinant protective protein from streptococcus pneumoniae
WO2002070665A2 (en) 2001-03-02 2002-09-12 The Rockefeller University Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
US20040023910A1 (en) * 2001-09-28 2004-02-05 Zhiming Zhang Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1480692A2 (de) 2002-03-07 2004-12-01 Merck & Co., Inc. Klinische spritze mit elektrischen stimulationsaspekten
NZ537256A (en) 2002-05-23 2007-09-28 Gendel Ltd Ablation device using electric field to sensitise the target tissue and ultrasound to treat the tissue
JP4563171B2 (ja) 2002-05-24 2010-10-13 シェーリング コーポレイション 中和ヒト抗igfr抗体
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US7291604B2 (en) 2003-09-03 2007-11-06 The General Hospital Corporation Methods of treating restenosis
WO2005099367A2 (en) 2004-04-16 2005-10-27 Critical Care Innovations, Inc. Systems and methods for improving image-guided tissue ablation
FR2880808A1 (fr) * 2005-01-20 2006-07-21 Yves Scherman Dispositif pour l'administration de principe actif aux cellules et tissus a l'aide d'electrodes de surface non invasives
US8101169B2 (en) * 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
US7923251B2 (en) * 2005-02-23 2011-04-12 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for avalanche-mediated transfer of agents into cells
EP1881845B1 (de) 2005-04-25 2010-03-24 Merial Ltd. Nipah-virus-impfstoffe
CN101437539B (zh) 2005-07-05 2013-10-02 康奈尔研究基金会(有限公司) 通过干扰cd99l2阻断白细胞迁出和炎症
FR2889066B1 (fr) * 2005-07-28 2007-11-09 Centre Nat Rech Scient Procede d'immunisation genetique par electrotransfert contre une toxine et antiserum susceptible d'etre obtenu par ledit procede
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
CA2629522A1 (en) 2005-11-14 2007-05-18 Merial Limited Gene therapy for renal failure
CA2666682C (en) 2006-10-19 2014-07-08 Merck & Co., Inc. Anti-il-13r.alpha.1 antibodies and their uses thereof
ES2501947T3 (es) 2006-10-19 2014-10-02 Csl Limited Antagonistas de anticuerpos de alta afinidad del receptor alfa 1 de interleucina
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
KR101445903B1 (ko) 2007-05-02 2014-09-29 메리얼 리미티드 향상된 발현 및 안정성을 갖는 dna 플라스미드
AU2009231598B2 (en) 2008-04-04 2015-03-12 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same
US8093043B2 (en) 2008-06-04 2012-01-10 New York University β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
EP2147697A1 (de) 2008-07-21 2010-01-27 Centre National De La Recherche Scientifique-CNRS Verfahren und Vorrichtung zur Anwendung elektrischer Felder in leitfähiges Material
EP2156860A1 (de) 2008-08-20 2010-02-24 Centre National De La Recherche Scientifique-CNRS Verfahren zur Herstellung isolierter Elektroden zum Einfügen elektrischer Felder in ein leitfähiges Material
NZ592368A (en) 2008-11-05 2013-11-29 Wyeth Llc Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
MX2011005604A (es) 2008-11-28 2011-09-01 Merial Ltd Vacuna recombinante para influenza aviar y sus usos.
JP2013504600A (ja) 2009-09-14 2013-02-07 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア IL−15受容体αおよび/またはそれをコードする核酸分子を含むワクチンおよび免疫治療薬、ならびにそれを用いる方法
KR101851699B1 (ko) 2009-11-02 2018-04-24 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 구제역 바이러스(fmdv) 공통 단백질, 이를 위한 코딩 서열 및 이로부터 만들어진 백신
PE20121685A1 (es) 2009-12-28 2012-12-28 Merial Ltd Antigeno ndv recombinante y usos del mismo
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
WO2011097640A1 (en) 2010-02-08 2011-08-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
EP2544716B1 (de) 2010-03-12 2020-01-01 Boehringer Ingelheim Animal Health USA Inc. Rekombinante impfstoffe gegen den maul-und-klauenseuchevirus und verwendungen davon
ES2850973T3 (es) 2010-08-23 2021-09-01 Wyeth Llc Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis
ES2585328T5 (es) 2010-09-10 2022-12-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
MX355501B (es) 2010-09-27 2018-04-20 Inovio Pharmaceuticals Inc Star Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.
CA2817709C (en) 2010-11-12 2021-06-01 The Trustees Of The University Of Pennsylvania Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
JP6099573B2 (ja) 2011-01-31 2017-03-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 新規なヘルペス抗原をコードする核酸分子、それを含むワクチン及びその使用方法
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EA032364B1 (ru) 2011-02-11 2019-05-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу
WO2012166450A1 (en) 2011-05-27 2012-12-06 Merial Limited Genetic vaccines against hendra virus and nipah virus
WO2012166493A1 (en) 2011-06-01 2012-12-06 Merial Limited Needle-free administration of prrsv vaccines
EP3662935A1 (de) 2011-07-11 2020-06-10 Inovio Pharmaceuticals, Inc. Kreuzprotektive arenavirus-impfstoffe und deren verfahren zur verwendung
KR102445129B1 (ko) 2011-12-12 2022-09-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
CA2858884A1 (en) 2011-12-12 2013-06-20 The Trustees Of The University Of Pennsylvania Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections
NZ722700A (en) 2012-02-14 2017-12-22 Merial Inc Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
CN104203274B (zh) 2012-02-14 2017-09-08 梅里亚股份有限公司 轮状病毒亚单位疫苗及其制备和使用的方法
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX2018011291A (es) 2012-03-09 2023-01-31 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
EA030866B1 (ru) 2012-03-22 2018-10-31 Мериал, Инк. Модифицированный вирус болезни марека и вакцины на его основе
MX363667B (es) 2012-04-10 2019-03-29 Univ Pennsylvania Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
US9597388B2 (en) 2012-04-12 2017-03-21 The Trustees Of The University Of Pennslyvania Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
CN110628822A (zh) 2012-06-13 2019-12-31 梅里亚有限公司 重配btv和ahsv疫苗
US10220082B2 (en) 2012-12-13 2019-03-05 Inovio Pharmaceuticals, Inc. WT1 vaccine
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
EP2964665B1 (de) 2013-03-08 2018-08-01 Pfizer Inc Immunogene fusionspolypeptide
KR102276405B1 (ko) 2013-03-15 2021-07-12 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 구제역 바이러스 (fmdv) 공통 단백질, 그에 대한 코딩 서열 및 그로부터 제조된 백신
BR112015022367B1 (pt) 2013-03-15 2021-06-22 The Trustees Of The University Of Pennsylvania Vacina, molécula de ácido nucleico, e, molécula de aminoácido
CA2919835A1 (en) 2013-07-31 2015-02-05 Board Of Trustees Of The University Of Arkansas Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens
KR101905278B1 (ko) 2013-09-08 2018-10-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CN105829341A (zh) 2013-12-13 2016-08-03 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法
WO2016089862A1 (en) 2014-12-01 2016-06-09 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20180041724A (ko) 2015-08-20 2018-04-24 메리얼 인코포레이티드 Fcv 재조합 백신 및 그의 용도
DK3355915T3 (da) 2015-09-29 2024-01-29 Boehringer Ingelheim Animal Health Usa Inc Vacciner af viruslignende partikel (vlp) af hundeparvovirus (cpv) og anvendelser deraf
NZ743236A (en) 2015-11-23 2019-12-20 Boehringer Ingelheim Animal Health Usa Inc Fmdv and e2 fusion proteins and uses thereof
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
AU2017214656B2 (en) 2016-02-05 2022-08-25 Inovio Pharmaceuticals, Inc. Cancer vaccines and methods of treatment using the same
AU2017249424B2 (en) 2016-04-13 2023-08-24 Janssen Pharmaceuticals, Inc. Recombinant arterivirus replicon systems and uses thereof
BR112019007433A2 (pt) 2016-10-17 2019-07-02 Synthetic Genomics Inc sistemas de replicon de vírus recombinante e usos dos mesmos
US11845939B2 (en) 2016-12-05 2023-12-19 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
KR102567845B1 (ko) 2017-01-31 2023-08-17 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
MX2020006226A (es) 2017-12-13 2020-11-18 Inovio Pharmaceuticals Inc Vacunas contra el cancer dirigidas a mesotelina y usos de estas.
JP2021506255A (ja) 2017-12-13 2021-02-22 イノビオ ファーマシューティカルズ,インコーポレイティド Prameを標的とするがんワクチンおよびその使用
BR112020010542A2 (pt) 2017-12-13 2020-12-01 Inovio Pharmaceuticals, Inc. moléculas de ácido nucleico, vetor, composição, proteínas, usos dos anteriores, e vacinas
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
WO2019123252A1 (en) 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) vaccines and uses thereof
SG11202005710YA (en) 2017-12-19 2020-07-29 Janssen Sciences Ireland Unlimited Co Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
JP2021511318A (ja) 2018-01-19 2021-05-06 ヤンセン ファーマシューティカルズ,インコーポレーテッド 組換えレプリコン系を使用する免疫応答の誘導および増強
CA3140748A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
WO2020255035A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyrimidine derivatives
US20220241402A1 (en) 2019-06-18 2022-08-04 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
WO2020254876A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Virus-like particle delivery of hepatitis b virus (hbv) vaccines
WO2020255010A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
JP2022536945A (ja) 2019-06-18 2022-08-22 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー B型肝炎ウイルス(HBV)ワクチンおよびHBVを標的化するRNAiの組合せ
WO2020255015A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
WO2020255013A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives
WO2020255017A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
WO2020255022A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
WO2020255008A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
US20220233684A1 (en) 2019-06-18 2022-07-28 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pd-l1 inhibitors
WO2020255019A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and a quinazoline derivative
CN114630675A (zh) 2019-06-18 2022-06-14 爱尔兰詹森科学公司 乙型肝炎病毒(hbv)疫苗和抗pd-1或抗pd-l1抗体的组合
WO2020255016A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
CA3140708A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
WO2020255018A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) vaccines and uses thereof
MA56520A (fr) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Co Construction de l'interleukine 12 recombinante et ses utilisations
WO2020255021A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor
WO2020255042A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and a pyrimidine derivative
EP3986460A2 (de) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Kombination aus hepatitis-b-virus (hbv)-impfstoffen und anti-pd-1-antikörper
US20220305118A1 (en) 2019-06-20 2022-09-29 Janssen Sciences Ireland Unlimited Company Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines
WO2020255062A1 (en) 2019-06-20 2020-12-24 Janssen Sciences Ireland Unlimited Company Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
IL298874A (en) 2020-06-12 2023-02-01 Univ Rochester Encoding and expression of ACE-tRNAs
AU2021303478A1 (en) 2020-07-08 2023-02-16 Janssen Sciences Ireland Unlimited Company RNA replicon vaccines against HBV
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
EP4267740A1 (de) 2020-12-28 2023-11-01 Arcturus Therapeutics, Inc. Auf hbv abzielende transkriptionsaktivator-ähnliche effektornukleasen (talens)
WO2023150753A1 (en) 2022-02-07 2023-08-10 University Of Rochester Optimized sequences for enhanced trna expression or/and nonsense mutation suppression
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4301794A (en) 1978-10-18 1981-11-24 Robert Tapper Method for iontophoretic treatment
US4411657A (en) 1980-05-19 1983-10-25 Anibal Galindo Hypodermic needle
JPS5810066A (ja) 1981-07-10 1983-01-20 株式会社アドバンス イオントフオレ−ゼ用プラスタ−構造体
US4441972A (en) 1983-04-08 1984-04-10 D.E.P. Systems, Inc. Apparatus for electrofusion of biological particles
US4476004A (en) 1983-04-08 1984-10-09 D.E.P. Systems, Inc. Apparatus for electrofusion of biological particles
US4639244A (en) 1983-05-03 1987-01-27 Nabil I. Rizk Implantable electrophoretic pump for ionic drugs and associated methods
DE3317415A1 (de) 1983-05-13 1984-11-15 Kernforschungsanlage Jülich GmbH, 5170 Jülich Kammer zur behandlung von zellen im elektrischen feld
US4622031A (en) 1983-08-18 1986-11-11 Drug Delivery Systems Inc. Indicator for electrophoretic transcutaneous drug delivery device
US4557723A (en) 1983-08-18 1985-12-10 Drug Delivery Systems Inc. Applicator for the non-invasive transcutaneous delivery of medicament
EP0140308B2 (de) 1983-10-20 2001-10-17 The Research Foundation Of State University Of New York Regulierung von Gen-Expression durch Translationshemmung unter Verwendung von m-RNS hinderndem Komplementär-RNS
US4578168A (en) 1984-07-27 1986-03-25 Biotronics Apparatus for fusing live cells with electric fields
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US6696420B1 (en) 1984-11-20 2004-02-24 Institut Pasteur Adenoviral vector with a deletion in the E1A coding region expressing a hetorologous protein
US4663292A (en) 1984-12-21 1987-05-05 Wong Daniel T High-voltage biological macromolecule transfer and cell fusion system
US4702732A (en) 1984-12-24 1987-10-27 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands
AT385894B (de) 1985-10-04 1988-05-25 Basem Dr Nashef Schlauchfoermige sonde
US5049488A (en) 1985-11-08 1991-09-17 Genentech, Inc. Method and nucleic acid for the preparation of lecithin:cholesterol acyltransferase
US4695547A (en) 1986-04-02 1987-09-22 Jeffrey L. Hilliard Probe for electrofusion, electroporation, or like procedure
US5744133A (en) 1986-08-13 1998-04-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor
FR2602790B1 (fr) 1986-08-13 1990-06-01 Transgene Sa Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante
US6007806A (en) 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
US4786277A (en) 1986-11-21 1988-11-22 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation
US5371003A (en) 1987-05-05 1994-12-06 Sandoz Ltd. Electrotransformation process
US5128257A (en) 1987-08-31 1992-07-07 Baer Bradford W Electroporation apparatus and process
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
ATE115999T1 (de) 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
EP0398960B1 (de) 1988-01-21 1995-12-06 Massachusetts Institute Of Technology Molekültransport durch gewebe mit der verwendung von elektroporation
US5389069A (en) 1988-01-21 1995-02-14 Massachusetts Institute Of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
US5547467A (en) 1988-01-21 1996-08-20 Massachusettes Institute Of Technology Method for rapid temporal control of molecular transport across tissue
US5749847A (en) 1988-01-21 1998-05-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5119832A (en) 1989-07-11 1992-06-09 Ravi Xavier Epidural catheter with nerve stimulators
US5124259A (en) 1989-08-23 1992-06-23 Mitsui Toatsu Chemicals, Inc. Method for electroporation
US6228844B1 (en) * 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US5236413B1 (en) 1990-05-07 1996-06-18 Andrew J Feiring Method and apparatus for inducing the permeation of medication into internal tissue
US5081990A (en) 1990-05-11 1992-01-21 New York University Catheter for spinal epidural injection of drugs and measurement of evoked potentials
EP0533816B1 (de) 1990-06-15 1995-06-14 Cortrak Medical, Inc. Vorrichtung zur abgabe von medikamenten
US5499971A (en) 1990-06-15 1996-03-19 Cortrak Medical, Inc. Method for iontophoretically delivering drug adjacent to a heart
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5501662A (en) 1992-05-22 1996-03-26 Genetronics, Inc. Implantable electroporation method and apparatus for drug and gene delivery
US5814603A (en) 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
JPH063783A (ja) 1992-06-19 1994-01-14 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5304120A (en) 1992-07-01 1994-04-19 Btx Inc. Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
JP3099049B2 (ja) * 1992-07-29 2000-10-16 農林水産省果樹試験場長 電気的細胞融合及び電気的核酸導入のための大量処理用電極
US5273525A (en) * 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5462520A (en) 1992-08-17 1995-10-31 Genetronics, Inc. Transsurface drug delivery by electrofusion of microbubbles to the tissue surface
US5688233A (en) 1992-08-17 1997-11-18 Genetronics, Inc. Electronincorporation enhanced transdermal delivery of molecules
US5464386A (en) 1992-08-17 1995-11-07 Genetronics, Inc. Transdermal drug delivery by electroincorporation of vesicles
US5318514A (en) 1992-08-17 1994-06-07 Btx, Inc. Applicator for the electroporation of drugs and genes into surface cells
JP3351572B2 (ja) 1992-10-05 2002-11-25 井上 聰一 イオンクロマトグラフィーによる分析体の分離・分析方法、イオンクロマトグラフィー用両荷電具備固定相及び多機能液体クロマトグラフィーによる分析体の分離・分析方法
US5468223A (en) 1992-11-30 1995-11-21 C.N.R.S. Paris Electrochemotherapy
FR2703253B1 (fr) 1993-03-30 1995-06-23 Centre Nat Rech Scient Applicateur d'impulsions electriques pour traitement de tissus biologiques.
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US5993434A (en) * 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
GB9317380D0 (en) * 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
DE4341424A1 (de) 1993-12-04 1995-06-08 Bosch Gmbh Robert Kraftstoffeinspritzpumpe
IL108775A (en) 1994-02-25 2003-09-17 Univ Ramot Method for efficient incorporation of molecules into cells
WO1996000111A1 (en) 1994-06-24 1996-01-04 Cygnus, Inc. Pulsatile delivery systems of biologically active agents using electro voltage pulsing for controlling membrane permeability
US5471884A (en) 1994-07-05 1995-12-05 Motorola, Inc. Gain-adjusting circuitry for combining two sensors to form a media isolated differential pressure sensor
IT235163Y1 (it) 1994-10-10 2000-03-31 Ideal Standard Spa Gruppo di tenuta per elementi maschio di stampi per la colatura di apparecchiature igienico-sanitarie
US5641680A (en) * 1994-11-14 1997-06-24 Zhao; Xi Gene transfer apparatus and method for using the same
US5810762A (en) 1995-04-10 1998-09-22 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
WO1997007826A1 (en) * 1995-08-29 1997-03-06 Cbr Laboratories, Inc. In vivo electroporation of cells
FR2738842B1 (fr) 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US5944710A (en) 1996-06-24 1999-08-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
US5944726A (en) 1996-08-23 1999-08-31 Scimed Life Systems, Inc. Stent delivery system having stent securement means
US5960974A (en) 1996-10-03 1999-10-05 Advance Engineered Products Ltd. Intermodal bulk container
JPH10234366A (ja) 1997-02-26 1998-09-08 Hisamitsu Pharmaceut Co Inc エレクトロポレーション用電極及びその製法、それを用いた製剤
KR100427786B1 (ko) * 1997-04-03 2004-04-30 일렉트로우펙트 에이에스 약물과 핵산의 골격 근육 내 주입 장치 및 방법
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) * 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
WO1999036563A1 (en) 1998-01-14 1999-07-22 Emed Corporation Electrically mediated cellular expression
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
CA2337652C (en) * 1998-07-13 2013-03-26 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field

Also Published As

Publication number Publication date
CZ299473B6 (cs) 2008-08-06
JP2002507985A (ja) 2002-03-12
US20030073653A1 (en) 2003-04-17
DE69826124T3 (de) 2007-10-11
HUP0004589A1 (hu) 2001-04-28
DE69826124T2 (de) 2005-09-15
KR20010020571A (ko) 2001-03-15
CN1261807A (zh) 2000-08-02
IL133710A0 (en) 2001-04-30
WO1999001158A1 (fr) 1999-01-14
NO996542D0 (no) 1999-12-29
ATE275423T1 (de) 2004-09-15
CA2294793A1 (fr) 1999-01-14
EP0991426B2 (de) 2007-03-28
NO996542L (no) 2000-02-17
CZ475599A3 (cs) 2000-07-12
EP0991426B1 (de) 2004-09-08
EP0991426A1 (de) 2000-04-12
AU8444798A (en) 1999-01-25
NO328102B1 (no) 2009-12-07
US6939862B2 (en) 2005-09-06
PL337583A1 (en) 2000-08-28
HUP0004589A3 (en) 2003-08-28
BR9810369A (pt) 2000-09-05

Similar Documents

Publication Publication Date Title
DE69826124D1 (de) Verabreichung der nukleinsäure in den quergestreiften muskel
EP0796081B1 (de) Elektrophoretischer apparat und verfahren zur anwendung von therapeutischen-, kosmetischen- und farblösungen im haar
WO2001085202A3 (en) Electroporation for introduction of molecules into cells
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
EA200300381A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
DK1023107T3 (da) Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen
WO2001089455A3 (en) System and method for assessing the performance of a pharmaceutical agent delivery system
ATE113295T1 (de) Tumornekrosefaktor, verfahren zu seiner herstellung, denselben enthaltende zusammensetzungen, dafür kodierende dns und diese dns verwendendes testverfahren.
DE69837274D1 (de) Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten
DK0559884T4 (da) Rekombinante virusvektorer til ekspression i muskelceller
UA91675C2 (ru) Формула полинуклеотидной вакцины против дыхательных паталогий и паталогий размножения свиней
HUP0004728A1 (hu) Javított eljárás nukleinsav bevitelére többsejtes eukarióta szervezet sejtjeibe és kombinált alkalmazása
IT1206311B (it) Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso.
DE69833784D1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
IT1187828B (it) Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
EP0232523A3 (en) Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins
EA199901048A1 (ru) Увеличение электрической проводимости и сокращаемости с помощью двухфазного кардиостимулятора
EA200100583A1 (ru) Композиции, содержащие лактадгерин или его варианты, и способы их использования
DE19781038T1 (de) Keratinozytenwachstumsfaktor-2-Produkte
EP0219258A3 (de) Peptid-Antagonisten von Neurokinin-B und sie enthaltende ophthalmische Lösungen
DE69734586D1 (de) Retinoid-metabolisierendes protein
PT866861E (pt) Clonagem molecular e caracterizacao de moleculas relacionadas com relaxina e com a familia dos ligandos da insulina
DE69828902D1 (de) Polypeptide mit 5-aminolevulinsäure synthaseaktivität und deren nukleinsäuren
DK0811068T3 (da) Humane DNase I varianter
BR8606123A (pt) Eletrodo esofagico deglutivel em"fio de prumo"unipolar para estimulacao cardiaca trans-esofagica;eletrocardiograma esofagico;"holter"esofagico e outros exames

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: INSTITUT GUSTAVE ROUSSY, VILLEJUIF, FR